Drug Search Results
More Filters [+]

Cobicistat

Alternative Names: cobicistat, tybost, evotaz, prezcobix, stribild, symtuza
Latest Update: 2024-07-14
Latest Update Note: Clinical Trial Update

Product Description

Cobicistat is used to increase the amounts of atazanavir (Reyataz, in Evotaz ) in adults and children weighing at least 77 pounds (35 kg) or darunavir (Prezista, in Prezcobix ) in adults and children weighing at least 88 pounds (40 kg) in the blood when these medications are used to treat human immunodeficiency virus (HIV). Cobicistat is in a class of medications called pharmacokinetic boosters. It works by increasing the amount of atazanavir or darunavir in the body so that they can have a greater effect. (Sourced from: https://medlineplus.gov/druginfo/meds/a616029.html)

Mechanisms of Action: Integrase Inhibitor,CYP3A4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: HIV Infections | HIV Infections | HIV Infections

Known Adverse Events: Abdominal Pain | Headache | Pain Unspecified | Diarrhea | Flatulence

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cobicistat

Countries in Clinic: Australia, Belgium, China, France, Germany, Ireland, Italy, Netherlands, Spain, United Kingdom, United States

Active Clinical Trial Count: 16

Highest Development Phases

Phase 3: Acquired Immunodeficiency Syndrome|HIV Infections

Phase 1: Healthy Volunteers|Kidney Diseases|Malnutrition

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

F8394-101

P1

Recruiting

Healthy Volunteers

2024-10-31

28%

F8394-101

P1

Recruiting

Healthy Volunteers

2024-10-31

28%

LAPTOP

P3

Active, not recruiting

HIV Infections|Acquired Immunodeficiency Syndrome

2024-06-01

2021-000738-32

P1

Active, not recruiting

HIV Infections

2023-03-15

PBI-200-106

P1

Completed

Healthy Volunteers

2022-11-12

28%

PBI-200-106

P1

Completed

Healthy Volunteers

2022-11-12

28%

Recent News Events